rise
incid
atop
diseas
includ
asthma
past
sever
decad
limit
particular
geograph
area
occur
develop
develop
countri
sever
factor
influenc
develop
sever
asthma
includ
atopi
environment
exposur
genet
predisposit
geneenviron
interact
stress
obes
diet
socioeconom
statu
infect
hygien
hypothesi
focus
attent
role
infect
develop
allerg
diseas
hypothesi
suggest
infect
earli
life
protect
effect
develop
asthma
atopi
research
suggest
howev
infect
may
caus
onset
persist
asthma
hit
run
hypothesi
pathogen
promot
dysregul
immun
system
lead
prolong
inflammatori
respons
even
pathogen
clear
thu
role
infecti
agent
develop
asthma
complex
evid
implic
infect
causal
protect
respect
asthma
develop
addit
potenti
role
infect
incept
asthma
infect
implic
common
precipit
asthma
exacerb
sever
clinic
observ
indic
asthma
episod
precipit
factor
allergen
exposur
mani
asthma
episod
preced
upper
respiratori
tract
symptom
may
last
sever
day
week
contrast
allergeninduc
asthma
exacerb
exposur
often
lead
rapid
onset
symptom
recoveri
time
approxim
hour
infect
link
asthma
exacerb
sinc
past
sever
decad
extens
investig
infecti
agent
relat
asthma
develop
exacerb
articl
examin
infect
trigger
asthma
focu
asthma
exacerb
respiratori
tract
infect
rti
common
caus
acut
ill
adult
children
upper
respiratori
infect
uri
constitut
major
ill
adult
typic
experi
two
four
uri
per
year
children
may
uri
per
year
rti
major
caus
visit
primari
care
physician
associ
signific
work
school
absente
estim
million
lost
workday
annual
consequ
rti
great
econom
impact
estim
cost
billion
annual
unit
state
numer
virus
produc
uri
tabl
symptom
pattern
common
mani
virus
difficult
determin
clinic
specif
viral
etiolog
acut
ill
tabl
viral
infect
commonli
trigger
asthma
exacerb
note
nearli
half
asthma
exacerb
adult
even
greater
percentag
exacerb
children
demonstr
studi
investig
role
viral
infect
asthma
exacerb
children
year
age
asthma
peak
expiratori
flow
pef
rate
perform
twice
daili
upper
lower
respiratori
tract
symptom
record
daili
virolog
sampl
obtain
within
hour
increas
upper
lower
respiratori
symptom
fall
pef
lmin
child
baselin
parent
subject
felt
child
develop
cold
evid
viral
infect
detect
episod
respiratori
tract
symptom
fall
pef
highest
detect
rate
occur
report
episod
wheez
cough
upper
respiratori
tract
symptom
togeth
declin
pef
addit
sever
respiratori
ill
may
influenc
outcom
uri
sever
viral
infect
seem
like
mild
infect
lead
exacerb
asthma
viral
infect
note
often
sever
exacerb
asthma
milder
exacerb
advent
sensit
diagnost
tool
detect
specif
infecti
pathogen
detect
microbi
dna
rna
use
polymeras
chain
reaction
pcr
strengthen
evid
virus
primari
trigger
factor
asthma
exacerb
recent
studi
confirm
signific
increas
weight
averag
viral
identif
patient
age
asthma
exacerb
studi
use
pcr
compar
prepcr
studi
studi
suggest
viral
recoveri
occur
often
asthmat
patient
acut
exacerb
asymptomat
asthmat
nonasthmat
individu
almost
children
infect
rsv
age
common
caus
bronchiol
pneumonia
infant
vari
includ
cough
coryza
fever
irrit
anorexia
wheez
pharyng
vomit
diarrhea
unknown
age
nearli
individu
infect
commonli
caus
respiratori
ill
acut
bronchiti
includ
pharyng
occasion
otiti
media
may
bullou
ten
percent
infect
individu
develop
pneumonia
within
day
may
last
wk
caus
diseas
human
highli
transmiss
droplet
epidem
occur
everi
immun
long
last
long
incub
period
rang
wk
along
long
asymptomat
carriag
week
month
facilit
famili
spread
may
continu
month
respons
varieti
respiratori
diseas
includ
pneumonia
acut
bronchiti
less
commonli
pharyng
laryng
otiti
media
sinus
mani
infect
patient
asymptomat
mild
moder
ill
prolong
ill
may
present
cough
persist
wk
sometim
biphas
cours
assum
transmiss
persontoperson
via
infect
respiratori
secret
recurr
infect
common
especi
adult
tropic
lessdevelop
area
infect
seem
occur
earlier
life
unit
state
adult
antibodi
age
initi
infect
peak
age
anoth
import
observ
link
viral
infect
asthma
exacerb
season
pattern
distribut
viral
infect
asthma
exacerb
especi
sever
case
requir
hospit
studi
compar
asthma
exacerb
due
season
allergen
environment
trigger
viral
infect
strong
relationship
found
season
incid
asthma
viral
infect
although
correl
pollen
spore
count
similarli
viral
infect
major
identifi
risk
factor
autumn
asthma
exacerb
addit
viral
infect
rti
atyp
organ
mycoplasma
pneumonia
chlamydia
pneumonia
precipit
signific
proport
acut
episod
wheez
contribut
sever
persist
asthma
may
serv
initi
insult
lead
develop
asthma
human
rhinoviru
rv
caus
nearli
half
upper
respiratori
ill
although
rv
infect
initi
believ
limit
upper
airway
lower
airway
epitheli
rv
infect
demonstr
although
infect
lower
respiratori
tract
may
occur
mechan
viral
infect
includ
rv
provok
asthma
unclear
may
includ
direct
extens
upper
rti
lower
respiratori
tract
mechan
may
indirect
involv
effect
airway
respons
independ
direct
epitheli
damag
inflamm
associ
lower
rti
lrti
rv
infect
enhanc
immedi
latephas
respons
allergen
potenti
augment
allerg
inflamm
within
airway
precipit
asthma
exacerb
rv
infect
lead
profound
exacerb
asthma
respons
major
hospit
childhood
asthma
although
less
adult
rv
infect
associ
declin
lung
function
asthmat
compar
normal
subject
within
day
develop
rv
infect
rv
infect
augment
airway
hyperrespons
day
experiment
rv
infect
effect
pronounc
sever
cold
rise
airway
hyperrespons
accompani
increas
nasal
interleukin
il
rvinfect
group
day
increas
nasal
day
correl
significantli
chang
airway
respons
day
coronaviru
second
common
viru
associ
asthma
episod
children
adult
infect
due
coronaviru
may
associ
less
sever
lower
respiratori
tract
symptom
infect
virus
suggest
find
coronavirusassoci
asthma
episod
asthmat
schoolag
children
associ
smaller
median
declin
pef
lmin
compar
episod
trigger
virus
lmin
studi
elderli
adult
coronaviru
associ
lower
respiratori
ill
patient
one
quarter
patient
consult
medic
practition
receiv
antibiot
impress
observ
coronaviru
infect
produc
greater
diseas
burden
valu
influenza
respiratori
syncyti
viru
influenza
viru
trigger
asthma
exacerb
age
group
addit
asthmat
individu
seem
suscept
death
associ
influenza
infect
observ
asian
pandem
time
cours
influenzainduc
asthma
exacerb
examin
retrospect
asthmat
children
year
age
acut
respiratori
symptom
fifteen
patient
decreas
fev
baselin
acut
stage
begin
onset
symptom
one
subject
whose
fev
decreas
incub
period
fev
decreas
maxim
second
day
ill
averag
improv
began
third
day
fev
return
within
normal
seventh
tenth
day
rate
adenovir
infect
declin
age
year
increas
except
pattern
infect
serotyp
whose
infect
rate
increas
age
infect
frequent
associ
wheez
demonstr
retrospect
chart
review
studi
wheez
note
nonasthmat
children
year
age
admit
intens
care
unit
adenovir
acut
lrti
studi
mortal
rate
gener
set
infect
adenovir
serotyp
adenovir
infect
demonstr
acut
asthma
episod
frequenc
adenovir
infect
substanti
lower
frequenc
rhinoviru
coronaviru
latent
adenovir
infect
may
role
genesi
asthma
furthermor
adenovir
shed
may
prolong
last
day
nasopharyng
swab
asymptomat
asthmat
children
healthi
control
subject
examin
pcr
adenoviru
dna
found
asthmat
children
compar
healthi
control
subject
adenoviru
recov
bronchoalveolar
lavag
bal
children
asthma
month
acut
infect
studi
bal
perform
children
mean
age
year
unfavor
respons
standard
corticosteroid
bronchodil
therapi
adenovir
infecti
trigger
asthma
antigen
detect
bal
fluid
balf
subject
repeat
studi
within
year
show
six
eight
subject
posit
adenoviru
two
occas
three
posit
sampl
three
time
cultur
balf
posit
adenoviru
cultur
perform
indic
viru
capabl
replic
similar
studi
perform
control
patient
without
persist
asthma
fail
detect
evid
adenoviru
respiratori
syncyti
viru
rsv
infect
almost
children
year
age
common
caus
bronchiol
pneumonia
infant
addit
caus
acut
lrti
rsv
serv
trigger
exacerb
asthma
chronic
lung
diseas
infant
experi
sever
rsv
bronchiol
seem
increas
frequenc
wheez
asthma
later
life
comparison
sever
retrospect
studi
children
admit
bronchiol
found
postbronchiol
group
significantli
higher
frequenc
bronchial
obstruct
symptom
year
later
pulmonari
function
studi
perform
diminish
fev
increas
bronchial
reactiv
compar
healthi
control
subject
find
confirm
prospect
studi
children
hospit
confirm
rsv
bronchiol
evalu
year
age
compar
ageand
gendermatch
control
subject
year
age
cumul
preval
asthma
rsv
group
versu
control
group
current
asthma
present
rsv
group
versu
control
group
howev
durat
effect
rsv
infect
asthmarel
symptom
appear
limit
prospect
studi
children
enrol
birth
develop
rsv
ltri
requir
hospit
first
year
life
compar
control
group
children
lrti
document
first
year
life
group
mild
rsv
lrti
substanti
increas
risk
frequent
wheez
year
age
odd
ratio
risk
frequent
wheez
remain
significantli
increas
year
age
time
prebronchodil
fev
postbronchodil
fev
significantli
lower
rsv
group
age
year
signific
betweengroup
differ
term
increas
risk
frequent
infrequ
wheez
studi
demonstr
rsv
bronchiol
signific
independ
risk
factor
subsequ
frequent
wheez
although
effect
seem
decreas
age
may
depend
upon
sever
rsv
infect
similar
adenovir
infect
persist
rsv
may
underli
part
sequela
sever
rsv
diseas
infect
may
lead
alter
pattern
local
interferon
chemokin
cytokin
product
potenti
lead
chronic
inflamm
furthermor
age
first
viral
infect
may
direct
pattern
diseas
later
life
gener
memori
respons
rsv
may
direct
respons
antigen
lung
toward
allerg
phenotyp
suggest
studi
mice
infect
rsv
differ
age
day
demonstr
stronger
respons
group
prime
youngest
age
reinfect
rsv
week
age
parainfluenza
virus
piv
caus
spectrum
respiratori
ill
similar
caus
rsv
result
fewer
hospit
ill
limit
upper
respiratori
tract
although
approxim
involv
lower
respiratori
tract
everi
children
infect
requir
hospit
although
less
common
rv
coronaviru
infect
piv
detect
episod
increas
symptom
decreas
pef
schoolag
children
frequent
sever
wheez
correl
elev
level
ige
antibodi
rsv
piv
nasal
secret
children
bronchiol
due
rsv
piv
human
metapneumoviru
hmpv
identifi
respiratori
sampl
children
respiratori
diseas
netherland
clinic
symptom
experienc
infect
individu
divers
may
consist
upper
lower
respiratori
tract
symptom
rang
otiti
media
bronchiol
croup
pneumonia
possibl
exacerb
asthma
hmpv
respons
worldwid
communityacquir
acut
rti
affect
children
age
group
mean
age
ill
month
male
predomin
malefemal
ratio
broad
epidem
season
evid
genet
variabl
suggest
may
one
serotyp
hmpv
wheez
part
clinic
symptomatolog
associ
hmpv
infect
half
otherwis
healthi
children
present
acut
respiratori
ill
evid
hmpv
infect
experienc
wheez
one
studi
seri
children
evid
hmpv
infect
bronchiol
common
diagnosi
patient
wheez
studi
evalu
specimen
collect
previous
healthi
children
acut
respiratori
ill
pathogen
identifi
detect
evid
hmpv
previous
neg
sampl
although
hmpv
infect
often
accompani
wheez
conflict
report
link
hmpv
infect
asthma
exacerb
nevertheless
bronchiol
common
caus
hospit
given
increas
hospit
rate
past
two
decad
possibl
hmpv
may
respons
portion
hospit
children
infecti
trigger
asthma
bronchiol
wheez
unrel
rsv
infect
furthermor
coinfect
rsv
hmpv
may
augment
sever
bronchiol
pneumonia
c
pneumonia
initi
evid
suggest
infect
pneumonia
c
pneumonia
associ
asthma
chronic
sever
case
report
suggest
associ
infect
atyp
organ
decreas
expiratori
flow
rate
increas
airway
hyperrespons
nonasthmat
individu
onset
asthma
symptom
previous
healthi
nonasthmat
adult
individu
present
complaint
malais
short
breath
gradual
onset
wheez
typic
resolv
treatment
macrolid
antibiot
oral
corticosteroid
symptom
may
progress
persist
illustr
adult
male
fever
sever
cough
short
breath
consolid
chest
radiograph
evid
pneumonia
infect
base
rise
serum
antibodi
titer
subsequ
develop
wheez
episod
revers
airway
obstruct
airway
reactiv
methacholin
infect
organ
persist
month
anim
studi
show
pneumonia
detect
pcr
day
infect
even
though
anim
becom
antibodi
cultur
neg
day
report
suggest
pneumonia
may
serv
caus
acut
wheez
trigger
factor
onset
asthma
comprehens
evalu
role
pneumonia
c
pneumonia
infect
patient
chronic
asthma
evalu
adult
patient
chronic
asthma
control
subject
use
pcr
cultur
serolog
detect
pneumonia
speci
c
pneumonia
speci
virus
nasopharynx
lung
blood
fiftysix
percent
asthmat
patient
posit
pcr
studi
pneumonia
n
c
pneumonia
n
mainli
found
balf
biopsi
sampl
control
subject
posit
pcr
find
pneumonia
cultur
organ
neg
patient
distinguish
featur
pcrposit
pcrneg
patient
significantli
greater
number
tissu
mast
cell
group
patient
pcr
posit
addit
signific
link
atyp
infecti
organ
asthma
exacerb
serolog
base
prospect
studi
adult
patient
hospit
exacerb
asthma
compar
hospit
surgic
patient
histori
lung
diseas
time
uri
month
admiss
seri
pneumonia
identifi
often
pathogen
asthmat
group
pneumonia
eight
c
pneumonia
influenza
five
influenza
b
three
two
one
six
adenoviru
two
rsv
three
pneumonia
five
legionella
spp
control
group
three
pneumonia
howev
patient
pneumonia
identifi
sole
infecti
agent
make
difficult
ascertain
culpabl
pneumonia
caus
hospit
studi
children
acut
wheez
agematch
healthi
children
detect
pneumonia
c
pneumonia
children
wheez
compar
respect
healthi
control
subject
children
infect
either
organ
treat
clarithromycin
improv
cours
diseas
observ
support
role
atyp
organ
exacerb
asthma
find
recent
confirm
french
seri
pneumonia
infect
found
c
pneumonia
infect
found
children
acut
asthma
exacerb
acut
pneumonia
infect
confirm
c
pneumonia
patient
experienc
first
wheez
episod
studi
need
confirm
associ
infect
asthma
exacerb
determin
preval
infect
patient
acut
exacerb
asthma
examin
infect
organ
modifi
sever
exacerb
respons
therapi
viralinduc
wheez
viw
character
brief
episod
lower
respiratori
symptom
decreas
pulmonari
function
set
acut
viral
uri
interspers
longer
asymptomat
period
normal
pulmonari
function
differ
classic
childhood
asthma
character
chronic
symptom
atopi
major
risk
factor
classic
asthma
viw
consid
two
differ
entiti
report
suggest
two
group
similar
characterist
benefit
similarli
prophylact
treatment
divis
wheez
phenotyp
especi
children
patient
viw
alon
seem
outgrow
symptom
age
howev
patient
pattern
viw
may
continu
adulthood
less
sever
symptom
neg
methacholin
challeng
pulmonari
function
remain
normal
inabl
reliabl
differenti
viw
asthma
especi
young
children
complic
evalu
influenc
viral
infect
exacerb
wheez
furthermor
heterogen
wheez
phenotyp
implic
term
efficaci
therapi
use
treat
episod
virus
typic
enter
bodi
contact
mucos
surfac
cellspecif
distribut
viral
receptor
determin
viral
tropism
viral
particl
intern
nucleic
acid
releas
transcript
product
viral
protein
start
viral
genom
replic
virion
one
earliest
respons
viral
infect
product
ifn
differ
cell
type
ifna
produc
leukocyt
ifnb
produc
fibroblast
infg
produc
cell
natur
killer
nk
cell
ifn
induc
transcript
mani
gene
includ
two
direct
antivir
activ
lead
increas
express
mhc
class
ii
gene
interferon
potent
activ
antivir
effector
cell
nk
cell
lymphocyt
macrophag
although
inflammatori
process
gener
viru
infect
gener
view
pattern
predomin
interferon
especi
infg
atopi
predomin
cytokin
profil
howev
viral
infect
promot
increas
cytokinemedi
inflamm
direct
induct
specif
cytokin
produc
differ
viral
agent
abil
certain
pathogen
stimul
product
cytokin
may
explain
certain
pathogen
strongli
associ
asthma
exacerb
other
virus
implic
incept
asthma
viral
infect
propens
lower
airway
involv
infanc
associ
chronic
lower
respiratori
tract
symptom
asthma
seem
particularli
relev
rsv
bronchiol
demonstr
signific
independ
risk
factor
subsequ
frequent
wheez
sequela
sever
rsv
diseas
could
explain
part
viral
persist
support
recent
studi
demonstr
persist
viral
genom
messeng
rna
lung
homogen
balbc
mice
day
post
rsv
infect
wherea
viru
could
longer
detect
balf
day
postinfect
anoth
possibl
mechan
viru
could
promot
asthma
gener
chang
pattern
proinflammatori
cytokin
product
could
facilit
viru
persist
demonstr
rsv
viral
infect
may
exert
direct
effect
airway
cell
increas
product
nonspecif
stimul
peripher
blood
mononuclear
cell
acut
convalesc
phase
rsv
infect
requir
hospit
demonstr
anim
studi
suggest
may
direct
effect
airway
smooth
muscl
regul
airway
tone
although
evid
support
role
viral
infect
develop
asthma
investig
necessari
confirm
hypothesi
mechan
could
allow
persist
latenc
viral
infect
poorli
understood
hypothes
asthmat
individu
increas
suscept
viral
infect
research
found
increas
incid
viral
infect
asthmat
children
compar
nonasthmat
pattern
could
explain
increas
express
receptor
rv
asthmat
subject
howev
find
confirm
studi
follow
cohabit
coupl
consist
atop
asthmat
healthi
nonatop
nonasthmat
individu
studi
subject
complet
daili
diari
card
upper
lower
respiratori
tract
symptom
measur
pef
twice
daili
nasal
aspir
taken
examin
rhinoviru
everi
week
rhinoviru
detect
sampl
asthmat
sampl
nonasthmat
particip
adjust
confound
factor
asthma
significantli
increas
risk
infect
rhinoviru
asthmat
individu
effect
atop
statu
rate
viral
infect
unclear
evid
exist
suggest
differ
rate
viral
infect
atop
nonatop
individu
even
lower
rate
viral
infect
among
atop
individu
although
studi
adequ
statist
power
confirm
trend
increas
risk
acut
wheez
atopi
combin
viral
infect
compar
atopi
viru
infect
alon
infant
famili
histori
atopi
seem
like
develop
bronchiol
higher
rate
hospit
even
asthmat
experi
frequent
infect
nonasthmat
possibl
asthmat
higher
incid
symptom
experienc
viral
infect
rhinovir
infect
greater
incid
symptom
asthmat
compar
nonasthmat
suggest
report
asthmat
experienc
seroconvers
influenza
viru
time
asthma
exacerb
even
absenc
sign
respiratori
infect
although
evid
support
role
infect
genesi
asthma
allergi
protect
effect
infect
develop
atopi
also
postul
invers
relationship
infect
allergi
first
note
studi
compar
white
famili
nativ
american
report
ige
level
preval
asthma
eczema
higher
white
popul
wherea
helminth
viral
bacteri
infect
preval
nativ
american
observ
increas
famili
size
often
associ
frequent
infect
earli
childhood
invers
relationship
preval
allerg
rhiniti
asthma
support
studi
report
invers
relationship
age
day
care
entri
diagnosi
asthma
one
potenti
explan
pattern
birth
predomin
respons
exposur
infect
occur
gradual
shift
toward
respons
howev
skew
immun
respons
regul
respons
viral
infect
impair
respons
would
infecti
trigger
asthma
predomin
favor
develop
allergi
ex
vivo
studi
shown
asthmat
expos
viral
infect
lack
capac
mount
strong
respons
clinic
effect
treatment
common
cold
mechan
viralinduc
wheez
asthma
elucid
new
form
treatment
may
emerg
involv
mani
inflammatori
pathway
suggest
antivir
antiinflammatori
therapi
potenti
role
intervent
onset
symptom
howev
combin
therapeut
approach
may
greatest
impact
prophylaxi
acquisit
viral
infect
form
vaccin
pharmacolog
therapi
offer
best
hope
diseas
control
major
obstacl
treatment
wide
varieti
organ
associ
uri
includ
viral
bacteri
agent
tabl
addit
accur
time
diagnosi
essenti
appropri
target
specif
antiinfect
therapi
rapid
rate
mutat
virus
lead
emerg
resist
strain
addit
difficulti
deliveri
expens
efficaci
drug
treatment
viral
rti
remain
symptomat
although
futur
approach
like
direct
toward
reduc
inflammatori
respons
elicit
viru
vaccin
remain
mainstay
prophylaxi
infect
howev
except
influenza
vaccin
develop
respiratori
virus
slow
disappoint
influenza
vaccin
contain
three
strain
two
one
b
inactiv
viru
one
two
modifi
yearli
base
upon
predict
upcom
viral
strain
produc
embryon
hen
egg
highli
immunogen
confer
protect
vaccin
recipi
minim
advers
effect
wholecel
influenza
vaccin
longer
avail
current
vaccin
consist
subvirion
prepar
disrupt
lipid
membran
purifi
surfac
antigen
recent
liveattenu
coldadapt
trival
intranas
influenza
vaccin
flumist
introduc
contraind
asthmat
longstand
concern
influenza
vaccin
may
trigger
exacerb
asthma
address
multicent
random
doubleblind
placebocontrol
crossov
trial
patient
asthma
age
rang
year
studi
confirm
safeti
influenza
vaccin
asthmat
demonstr
frequenc
exacerb
asthma
similar
week
vaccin
activ
influenza
vaccin
placebo
respect
although
yearli
influenza
vaccin
recommend
routin
element
asthma
manag
recent
studi
gener
concern
use
influenza
vaccin
prevent
influenzarel
asthma
exacerb
random
doubleblind
placebocontrol
trial
show
number
sever
durat
influenzarel
asthma
exacerb
similar
group
receiv
influenza
vaccin
group
receiv
placebo
cours
one
influenza
viru
season
vaccin
children
tend
shorter
exacerb
approxim
day
nonvaccin
children
antivir
therapi
target
sourc
infect
directli
decreas
number
infecti
agent
therefor
reduc
inflammatori
process
licens
antivir
therapi
direct
influenza
amantadin
rimantadin
influenza
b
zanamivir
oseltamivir
rsv
ribavirin
neuraminidas
inhibitor
zanamivir
oseltamivir
advantag
adamantan
amantadin
rimantadin
broader
spectrum
effect
b
strain
influenza
viru
inhibit
neuraminidas
whose
activ
site
consist
amino
acid
conserv
natur
occur
influenza
viru
prevent
cleavag
sialic
acid
newli
acquir
membran
leav
emerg
viru
inact
therebi
decreas
infect
neuraminidas
inhibitor
improv
respiratori
outcom
patient
asthma
acut
influenza
infect
ad
benefit
effect
prophylaxi
influenza
infect
although
gener
well
toler
case
report
bronchospasm
treatment
inhal
zanamivir
howev
difficult
separ
symptom
effect
influenza
infect
disadvantag
current
antivir
therapi
specif
influenza
need
initi
treatment
within
hour
onset
infect
toxic
profil
ribavirin
approv
use
sever
rsv
infect
limit
clinic
use
except
set
sever
ill
immunocompromis
host
antibiot
use
appropri
evid
bacteri
infect
contribut
asthma
exacerb
although
pyogen
lung
infect
rare
exacerb
asthma
rare
associ
wheez
although
macrolid
antibiot
report
antivir
effect
vitro
rhinovirus
effect
confirm
vivo
recent
cochran
review
support
use
antibiot
treatment
common
cold
antiinflammatori
effect
macrolid
antibiot
limit
abil
interfer
corticosteroid
metabol
evidenc
inhibit
neutrophil
oxid
burst
reduct
cytokin
format
reduct
product
asthmat
patient
infect
pneumonia
c
pneumonia
may
benefit
prolong
treatment
clarithromycin
evidenc
signific
improv
fev
furthermor
doubleblind
random
crossov
studi
patient
stabl
mild
moder
asthma
evalu
pneumonia
c
pneumonia
receiv
mg
clarithromycin
placebo
twice
daili
week
methacholin
respons
improv
patient
week
clarithromycin
treatment
improv
airway
hyperrespons
week
clarithromycin
treatment
confirm
group
patient
asthma
receiv
concomit
therapi
inhal
corticosteroid
select
basi
infect
pneumonia
c
pneumonia
remain
unclear
mechan
macroinfecti
trigger
asthma
lide
antibiot
improv
airway
hyperrespons
patient
asthma
possibl
may
includ
treatment
occult
chronic
infect
interfer
steroid
metabol
antiinflammatori
properti
class
antimicrobi
although
intern
guidelin
manag
asthma
rel
pauciti
evid
regard
therapeut
strategi
specif
viw
asthmat
healthi
subject
acut
exacerb
asthma
induc
viral
infect
mani
form
asthma
therapi
especi
inhal
corticosteroid
reduc
frequenc
sever
exacerb
one
would
presum
current
treatment
chronic
asthma
would
efficaci
prevent
viw
howev
vari
phenotyp
wheez
especi
childhood
seem
respond
differ
manag
approach
particularli
true
rsvassoci
wheez
consist
respond
medic
often
use
treat
asthma
exacerb
includ
bronchodil
corticosteroid
thu
despit
efficaci
inhal
corticosteroid
control
asthma
reduct
exacerb
patient
continu
experi
exacerb
particularli
set
viral
rti
sever
treatment
approach
investig
attempt
reduc
morbid
associ
wheez
associ
rti
brunett
et
al
examin
effect
short
cours
oral
corticosteroid
administ
unblind
manner
onset
uri
symptom
group
children
histori
recurr
wheez
set
viral
infect
period
group
receiv
oral
corticosteroid
earli
sign
rti
experienc
reduct
frequenc
wheez
emerg
room
visit
hospit
howev
recent
doubleblind
placebocontrol
trial
evalu
use
parentiniti
oral
corticosteroid
earli
sign
episod
presum
viralinduc
wheez
detect
differ
oral
corticosteroid
therapi
placebo
term
symptom
score
rate
hospit
thu
role
use
oral
corticosteroid
earli
sign
ill
children
recurr
viral
wheez
unclear
addit
investig
requir
determin
efficaci
approach
manag
attenu
wheez
episod
repeat
use
system
corticosteroid
episod
remain
clinic
concern
given
efficaci
inhal
corticosteroid
ic
daili
manag
asthma
favor
safeti
profil
compar
system
corticosteroid
use
ic
manag
viw
explor
although
ic
effect
manag
persist
asthma
current
evid
suggest
lack
efficaci
regular
use
ic
patient
mild
viw
recent
metaanalysi
conclud
use
ic
episod
viraltrigg
wheez
children
use
mainten
may
decreas
rate
oral
corticosteroid
requir
patient
receiv
daili
ic
therapi
common
clinic
practic
doubl
dose
ic
onset
asthma
exacerb
shown
ineffect
prevent
symptom
progress
howev
recent
studi
adult
demonstr
valuabl
effect
quadrupl
ic
dose
acut
asthma
exacerb
data
suggest
corticosteroid
taken
oral
inhal
may
use
treatment
prevent
therapi
asthma
exacerb
set
rti
cysteinyl
leukotrien
cyslt
identifi
import
mediat
complex
pathophysiolog
asthma
cyslt
detect
blood
urin
nasal
secret
sputum
balf
patient
chronic
asthma
elev
cyslt
detect
respiratori
secret
children
viral
induc
wheez
similar
elev
level
asthmat
infant
prolong
persist
wheez
mean
month
histori
viral
ill
wheez
onset
signific
elev
leukotrien
bal
despit
fact
infant
receiv
daili
ic
therapi
mgd
find
suggest
similar
asthma
pathophysiolog
cyslt
play
role
pathophysiolog
viralinduc
wheez
addit
base
studi
cyslt
fulli
suppress
prefer
standard
antiinflammatori
therapi
inhal
corticosteroid
thu
antagon
effect
cyslt
use
leukotrien
receptor
antagonist
may
provid
clinic
benefit
patient
viw
rel
efficaci
intervent
strategi
aim
reduct
wheez
asthma
set
rti
depend
upon
wheez
phenotyp
probabl
time
initi
therapi
investig
therapeut
approach
viw
ongo
may
provid
insight
optim
treatment
approach
challeng
condit
infect
implic
asthma
exacerb
incept
asthma
sever
studi
support
concept
virus
atyp
infecti
agent
may
induc
asthma
exacerb
contribut
chronic
asthma
elucid
mechan
underli
interact
infecti
agent
asthma
lead
improv
treatment
prevent
exacerb
studi
need
explor
vast
domain
infecti
trigger
asthma
exacerb
